Satellite Banner
Technology Networks Header
Sunday, September 21, 2014
Technology Networks
 
Register | Sign in
Home Page
  Permissions

Permission to use, copy and distribute documents presented on this World Wide Web site and related graphics is not granted without prior written permission of Technology Networks Ltd

To obtain this permission contact:
Technology Networks Ltd
Unit 6, Woodview
Bull Lane
Acton
Sudbury
CO10 0FD, U.K.

In cases where permission is granted, it is done so under the provision that the above copyright notice and this permission notice appear in all copies. All other rights are reserved.

The information and data included in the TechnologyNetworks.com WWW site, and all its affiliated websites and associated email newsletters, have been compiled from a variety of sources, and are subject to change without notice. Technology Networks Ltd. makes no warranties or representations whatsoever regarding the quality, content, completeness, or adequacy of this information and data.

Technology Networks Ltd. specifically disclaims all warranties with respect to this WWW site, email newsletters or your use thereof, express, implied, or otherwise, including without limitation, all warranties of merchantability and fitness for a particular purpose. Technology Networks Ltd shall not be liable for any special, incidental, or consequential damages, including, without limitation, lost revenues, lost profits, or loss of prospective economic advantage, resulting from the use or misuse of this site, or the information therein.

Scientific News
Novel Drug Targeting Leukemia Cells Enters Clinical Trial
Phase 1 human clinical trial to assess the safety and efficacy of a new monoclonal antibody for CLL patients.
Researchers Discover What Lies Behind the Death of Stem Cells
Researchers have identified key processes that control stem cell survival, providing insights that could improve their use in medicine.
Genetic Testing for Prostate Cancer
Genetic testing can identify men at six-fold increased risk of prostate cancer.
Redefining High Risk Patients With Stage II Colon Cancer
microRNA-21 identified as an independent prognostic biomarker.
Leukemia Subtype Becomes More Common With Age
Genomic Analysis of 1,725 patients reveals the prevalence of Ph-like ALL increases with age.
Ovarian Cancer Oncogene Found in "Junk DNA"
The study is published online in this week in Cancer Cell.
New Genetic Target for a Different Kind of Cancer Drug
Upstream of the proteins that cancer cells use to proliferate sits RBM4, a gene-splicing protein that is drastically reduced in human lung and breast cancer cells.
Combination microRNA Therapy Suppresses Non-Small-Cell Lung Cancer
Findings offer a promising therapeutic avenue for NSCLC.
Breakthrough Melanoma Treatment, Keytruda, Developed
New immunotherapy launched in the US for treatment of adults with advanced melanoma, developed using antibody humanization expertise at UK’s MRC Technology.
New Gene Mutations for Wilms Tumor
UT Southwestern researchers identified the mutated genes by sequencing the DNA of 44 tumors.
Skyscraper Banner
Skyscraper Banner
Follow TechNetcom1 on Twitter
Technology Networks Ltd. on LinkedIn
Go to LabTube.tv